Publications by the researcher in collaboration with Javier Diez Domingo (37)

2024

  1. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

  2. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. 95-107

2023

  1. Addressing influenza’s underestimated burden – Iberian experts call to action

    BMC Infectious Diseases

  2. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015–2018

    BMC Infectious Diseases, Vol. 23, Núm. 1

  3. Excess hospitalizations and mortality associated with seasonal influenza in Spain, 2008–2018

    BMC Infectious Diseases, Vol. 23, Núm. 1

  4. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age

    The Journal of infectious diseases, Vol. 227, Núm. 11, pp. 1293-1302

2022

  1. A tool for early estimation of influenza vaccination coverage in Spanish general population and healthcare workers in the 2018–19 season: the Gripómetro

    BMC Public Health, Vol. 22, Núm. 1

  2. Clinical and economic burden of physician-diagnosed influenza in adults during the 2017/2018 epidemic season in Spain

    BMC Public Health, Vol. 22, Núm. 1

  3. Clinical and economic burden of respiratory syncytial virus in Spanish children: the BARI study

    BMC Infectious Diseases, Vol. 22, Núm. 1

  4. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

    The Lancet, Vol. 399, Núm. 10340, pp. 2047-2064

2020

  1. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain

    PLoS ONE, Vol. 15, Núm. 5

  2. Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial

    The Pediatric infectious disease journal, Vol. 39, Núm. 1, pp. e1-e10

2019

  1. Anamnestic immune response and safety of an inactivated quadrivalent influenza vaccine in primed versus vaccine-naïve children

    Pediatric Infectious Disease Journal, Vol. 38, Núm. 2, pp. 203-210

  2. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6–35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres

    Vaccine, Vol. 37, Núm. 13, pp. 1876-1884

  3. Evaluation of a Hexavalent-Pentavalent-Hexavalent Infant Primary Vaccination Series Followed by a Pentavalent Booster Vaccine in Healthy Infants and Toddlers

    Pediatric Infectious Disease Journal, Vol. 38, Núm. 3, pp. 317-322

  4. ¿Qué hemos aprendido sobre rotavirus en España en los últimos 10 años?

    Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP ), Vol. 91, Núm. 3, pp. 166-179

2018

  1. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial

    Vaccine, Vol. 36, Núm. 38, pp. 5781-5788

  2. Prevention of vaccine-matched and mismatched influenza in children aged 6–35 months: a multinational randomised trial across five influenza seasons

    The Lancet Child and Adolescent Health, Vol. 2, Núm. 5, pp. 338-349

2017

  1. Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

    CMAJ, Vol. 189, Núm. 41, pp. E1276-E1285

2016

  1. Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age

    Pediatric Infectious Disease Journal